<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 27, 2018 (HealthDay News) — Delayed administration of sodium thiosulfate after cisplatin chemotherapy may prevent treatment-related hearing loss in children with standard-risk hepatoblastoma without affecting survival outcomes, according to a study published online June 21 in the New England Journal of Medicine<\/i>.<\/p>\n
Penelope R. Brock, M.D., Ph.D., from Great Ormond Street Hospital in London, and colleagues randomly assigned children (older than 1 month to younger than 18 years of age) who had standard-risk hepatoblastoma to receive cisplatin alone (n = 52; 80 mg per m2<\/sup> of body-surface area over six hours) or cisplatin plus sodium thiosulfate (n = 57; 20 g per m2<\/sup> over a 15-minute period, six hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses. Pure-tone audiometry was used to measure absolute hearing threshold in 101 of the children.<\/p>\n The researchers found that few high-grade toxic effects were associated with sodium thiosulfate. In 33 percent of children in the cisplatin-sodium thiosulfate group and 63 percent in the cisplatin-alone group, hearing loss of grade 1 or higher occurred, which indicated a 48 percent lower incidence of hearing loss in the cisplatin-sodium thiosulfate group. At a median of 52 months of follow-up, the three-year rates of event-free survival were 82 percent in the cisplatin-sodium thiosulfate group and 79 percent in the cisplatin-alone group, while the three-year rates of overall survival were 98 percent and 92 percent, respectively.<\/p>\n “We found that the delayed administration of sodium thiosulfate resulted in a significantly lower incidence of cisplatin-induced hearing loss, with no evidence of tumor protection,” conclude the authors.<\/p>\n Several authors disclosed ties to Fennec Pharmaceuticals.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n